Heat shock protein gp96 and cancer immunotherapy.
Heat shock protein gp96 is a highly conserved and monomorphic glycoprotein in the endoplasmic reticulum. It functions as molecular chaperone and can associate with a variety of antigenic peptides noncovalently in vivo and in vitro. Recent studies have indicated that gp96 molecules participate in major histocompatibility complex class I-restricted antigen presentation pathway. Immunization of mice with gp96 preparations isolated from cancer cells can elicit a cancer-specific protective T cell immune response that is recallable, which is a prerequisite for gp96 as a therapeutic vaccine against cancers. The immunogenicity of gp96 molecules has been attributed to the antigenic peptides associated with them. These phenomena provide a new pathway for cancer immunotherapy. The mechanism that the gp96-peptide complex induces specific immune response and the explorations for gp96-peptide complex as a therapeutic cancer vaccine are reviewed.
Peibin
Yue
Y
Cancer Institute & Hospital, CAMS & PUMC, Beijing 100021.
Shude
Yang
Y
Changzhi
Huang
H
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism; D018832:Molecular Chaperones / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000276:immunology / Q000378:metabolism
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; D018832:Molecular Chaperones; D010455:Peptides; C052646:sarcoma glycoprotein gp96 rejection antigens